Development of gamma-H2AX assay to assess toxicity and efficacy from chemotherapy in circulating tumor cells (CTCs) and peripheral blood lymphocytes

被引：0
|
作者：
Sheikh, Hassan S. [1 ]
Matthew, Elizabeth [1 ]
El-Deiry, Wafik S. [1 ]
机构：
[1] Penn State Hershey Canc Inst, Hershey, PA USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/1538-7445.AM2012-745
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
745
引用
收藏
页数：1
相关论文
共 50 条
  • [21] An Automated Microscopic Scoring Method for the γ-H2AX Foci Assay in Human Peripheral Blood Lymphocytes
    Nair, Shankari
    Cairncross, Samantha
    Miles, Xanthene
    Engelbrecht, Monique
    du Plessis, Peter
    Bolcaen, Julie
    Fisher, Randall
    Ndimba, Roya
    Cunningham, Charnay
    Martinez-Lopez, Wilner
    Schunck, Christian
    Vandevoorde, Charlot
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2021, (178):
  • [22] A novel method to quantify gamma H2AX foci in circulating tumor cells in patients receiving chemotherapy for colorectal cancer
    Saggese, Matilde
    Ensell, Leah
    Vesely, Clare
    Spanswick, Victoria
    Peruzzi, Elena
    Cunati, Diana
    Signorini, Giulio
    Hartley, John
    Arkenau, Hendrik Tobias
    Meyer, Tim
    CANCER RESEARCH, 2015, 75
  • [23] CIRCULATING TUMOR CELLS (CTCS) IN PERIPHERAL BLOOD OF BREAST CANCER PATIENTS BEFORE AND AFTER ADJUVANT CHEMOTHERAPY THE GERMAN SUCCESS-TRIAL
    Rack, B.
    Schindlbeck, C.
    Schneeweiss, A.
    Hilfrich, J.
    Lorenz, R.
    Jueckstock, J.
    Beckmann, M.
    Pantel, K.
    Lichtenegger, W.
    Sommer, H.
    Friese, K.
    Janni, W.
    ANTICANCER RESEARCH, 2008, 28 (6B) : 4048 - 4049
  • [24] Development and Clinical Prospects of Techniques to Separate Circulating Tumor Cells from Peripheral Blood
    Tian, Cheng
    Xu, Xinhua
    Wang, Yuke
    Li, Dailong
    Lu, Haiyan
    Yang, Ziwei
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 7263 - 7275
  • [25] Isolation and characterization of circulating tumor cells (CTCs) from peripheral blood specimens of patients with advanced solid tumor malignancies (using ApoStream™ instrumentation)
    Balasubramanian, Priya
    Wang, Lihua
    Lawrence, Scott M.
    Navas, Tony
    Kummar, Shivaani
    Hollingshead, Melinda
    Owusu, Francis
    Parchment, Ralph E.
    Tomaszewski, Joseph E.
    Doroshow, James H.
    Kinders, Robert J.
    CANCER RESEARCH, 2014, 74 (19)
  • [26] Circulating tumor cells (CTCs) in peripheral blood of breast cancer patients at primary diagnosis - A potential tool for risk stratification and monitoring of treatment efficacy
    Rack, Brigitte K.
    Schindlbeck, Christian
    Janni, Wolfgang
    Jeschke, Udo
    Hofmann, Simone
    Beckmann, Matthias W.
    Pantel, Klaus
    Lichtenegger, Werner
    Sommer, Harald
    Friese, Klaus
    ANNALS OF ONCOLOGY, 2006, 17 : 93 - 93
  • [27] Development of an Automated and Sensitive Microfluidic Device for Capturing and Characterizing Circulating Tumor Cells (CTCs) from Clinical Blood Samples
    Gogoi, Priya
    Sepehri, Saedeh
    Zhou, Yi
    Gorin, Michael A.
    Paolillo, Carmela
    Capoluongo, Ettore
    Gleason, Kyle
    Payne, Austin
    Boniface, Brian
    Cristofanilli, Massimo
    Morgan, Todd M.
    Fortina, Paolo
    Pienta, Kenneth J.
    Handique, Kalyan
    Wang, Yixin
    PLOS ONE, 2016, 11 (01):
  • [28] Prognostic relevance of circulating tumor cells (CTCs) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy: The German SUCCESS-Trial
    Rack, B. K.
    Schindlbeck, C.
    Schneeweiss, A.
    Hilfrich, J.
    Lorenz, R.
    Beckmann, M. W.
    Pantel, K.
    Lichtenegger, W.
    Sommer, H. L.
    Janni, W. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [29] In vitro evaluation of the genotoxicity of CeO2 nanoparticles in human peripheral blood lymphocytes using cytokinesis-block micronucleus test, comet assay, and gamma H2AX
    Konen-Adiguzel, Serpil
    Ergene, Serap
    TOXICOLOGY AND INDUSTRIAL HEALTH, 2018, 34 (05) : 293 - 300
  • [30] Measurement of gamma-H2AX in circulating tumor cells (CTC) from patients receiving ABT-888 (veliparib) in combination with carboplatin on a phase I dose-escalation study (OSU-10080/NCI8609).
    Garcia-Villa, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
12345